#280: A Healthcare Stock on Emmet’s Watchlist

#280: A Healthcare Stock on Emmet’s Watchlist

Author: MyWallSt October 2, 2025 Duration: 51:23

This week, Mike and Emmet venture onto the shores of the healthcare industry to identify some potential hundred-baggers.

Emmet breaks down Oscar Health, a stock often discussed by investors on X and Reddit. The company was founded to bring technological disruption to the health insurance market, particularly among providers and plans operating under the Affordable Care Act. It has solid revenue growth, narrowing losses, and a strong leadership team—but it could still fall victim to sector restructuring.

Mike takes on Medpace Holdings, a clinical research provider that helps biotechs outsource their testing and trials. The company has shown consistent growth and operates a business model that eliminates many of the risks of investing directly in pharma. However, its stock may now be prohibitively expensive after an eye-watering run-up earlier this year.

Both of these stocks come from our premium products, Horizon and Nexus, so you won’t want to miss this sneak peek.

Apologies for Mike’s sound—he was recording next to a construction site.


Our Horizon portfolio is a boutique service led by our co-founder and lead investor, Emmet Savage. Emmet has built his career on finding life-changing investments and believes the next hundred-bagger is already within his holdings. According to 100-bagger expert Chris Mayer, “no one owns more 100-baggers than Emmet.”

To claim your exclusive Horizon discount, head to mywallst.com/horizon or email us at pod@mywallst.com.


Become a successful investor by checking out all the content MyWallSt has to offer:

📩 Email us: pod@mywallst.com

📚 Learn the fundamentals of investing by downloading our free Learn app: https://bit.ly/3DXPOz7

💻 Keep updated on stock market news by visiting our blog: https://mywallst.com/blog/

🎧 Tune in to our podcast Stock Club to stay updated on weekly news: https://mywallst.com/stock-investment-podcast/

🎉 Follow MyWallSt on social:

❌ X: @MyWallStHQ

💃 TikTok: @MyWallSt

📸 Instagram: @MyWallSt

🖥️ Facebook: @MyWallSt

👔 LinkedIn: MyWallSt


Each week on Stock Club, the team from MyWallSt gathers to break down the movements and ideas shaping the market. This isn't about hype or frantic trading tips; it's a grounded conversation focused on understanding how investing actually works. You'll hear them analyze specific stock news and discuss the strategies behind building lasting wealth, all with the aim of making you a more thoughtful and confident investor. The discussion in this podcast naturally evolves from the week's most significant events, offering clarity on complex financial stories without relying on jargon. Tuning in feels like being part of a straightforward, informed discussion where the priority is long-term perspective over short-term noise. For anyone looking to deepen their grasp of the business and investing landscape, Stock Club provides a consistent, reliable space to learn. It’s the regular check-in that helps demystify the market's shifts, emphasizing education and insight as the true foundations for success. You can find Stock Club wherever you listen to podcasts.
Author: Language: English Episodes: 50

Stock Club
Podcast Episodes
#309: 2 Legacy Stocks for Long-term Investing [not-audio_url] [/not-audio_url]

Duration: 43:30
With all the talk of IPOs and upstarts, it’s a great time to remember that legacy players can still pack a punch. This week, we look at two companies that have been on public markets for decades and have been all over th…
#308: The Best and Worst Business Pivots [not-audio_url] [/not-audio_url]

Duration: 46:15
In light of Allbirds’ (NASDAQ: BIRD) head-scratching transition to an AI compute infrastructure company, Mike and Emmet break down some of the market’s best and worst business pivots.In simple terms, a pivot is when a bu…
#307: Is SpaceX’s IPO a Buy? [not-audio_url] [/not-audio_url]

Duration: 50:49
This week, we’re discussing one of the most significant IPOs of all time: SpaceX.While space travel began as a government-led effort, over the past few decades it has increasingly become the domain of the private sector.…
#306: Ireland’s New Investment Scheme Explained [not-audio_url] [/not-audio_url]

Duration: 38:09
The day we’ve been hoping for is finally here. The Irish government has announced a new investing scheme to provide people in Ireland with an easy, tax-efficient way to access the markets. There are hundreds of billions…
Stock Red Flags to Avoid Before They Destroy Your Portfolio [not-audio_url] [/not-audio_url]

Duration: 47:17
We normally talk about the characteristics we love to find in stocks. But this week, we bring you all the things we hate. We’ve all gotten caught in a hype cycle or seen an investment thesis degrade, so having a list of…
2 Australian (ASX) Stocks to Buy Right Now [not-audio_url] [/not-audio_url]

Duration: 40:01
Investor Down Under — g’day. We’ve long loved hunting for underappreciated stocks abroad, and over the years we’ve realized Australia is a particularly great place to find them. With its investing culture on the rise, th…
#303: The AI Stocks No One is Talking About: Biotech Boom [not-audio_url] [/not-audio_url]

Duration: 47:38
This week, Emmet and Mike are digging into one of the hottest trends of our futuristic world: human longevity. We’ve all seen Bryan Johnson on our social feeds, but the business of living longer is more than just a meme.…
#302: The One Metric You Need to Find Multibagger Stocks [not-audio_url] [/not-audio_url]

Duration: 45:29
We’ve pitched you businesses and described graphs, but this week Mike and Emmet put the power in your hands and teach you how to find multibagger stocks. And it can be as simple as one metric: insider ownership.Inspired…
#301: The 6 Best Dividend Stocks to Buy [not-audio_url] [/not-audio_url]

Duration: 54:02
This week, we’re heading to safer shores — trading moonshots for mailboxes — and bringing you Emmet and Mike’s favorite dividend stocks.We’re growth investors at heart and would usually rather see smart R&D spending than…